| Popis: |
Thrombocytopenia is a well-known complication post bone marrow transplant, whether primary or secondary. Refractory thrombocytopenia is not uncommon and over the past few years, thrombopoietin receptor agonists have emerged as new agents for the management of the above. Namely Eltrombopag and more recently Romiplostim. In children however, though Eltrombopag is being more frequently used, Romiplostim usage is still rarely reported for management of thrombocytopenia post bone marrow transplantation. Our experience with Romiplostim was successful in the management of refractory thrombocytopenia in a child with MDS post bone marrow transplantation. |
